.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
McKinsey
AstraZeneca
Colorcon
Chubb
US Army
Citi
Medtronic
Covington
Healthtrust

Generated: November 21, 2017

DrugPatentWatch Database Preview

Sandoz Inc Company Profile

« Back to Dashboard

What is the competitive landscape for SANDOZ INC, and what generic alternatives to SANDOZ INC drugs are available?

SANDOZ INC has one hundred and forty-four approved drugs.

There are two US patents protecting SANDOZ INC drugs. There are fifteen tentative approvals on SANDOZ INC drugs.

There are twenty patent family members on SANDOZ INC drugs in eighteen countries and one hundred and ninety-five supplementary protection certificates in twelve countries.

Summary for Sandoz Inc

International Patents:20
US Patents:2
Tradenames:117
Ingredients:112
NDAs:144
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz Inc
OXALIPLATIN
oxaliplatin
INJECTABLE;IV (INFUSION)078812-001Aug 7, 2009DISCNNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
DOXYCYCLINE
doxycycline
TABLET;ORAL065353-002Nov 27, 2006DISCNNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
ISIBLOOM
desogestrel; ethinyl estradiol
TABLET;ORAL-28202789-001Aug 12, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
SUMATRIPTAN SUCCINATE
sumatriptan succinate
INJECTABLE;SUBCUTANEOUS078067-002Feb 6, 2009DISCNNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
OLANZAPINE
olanzapine
INJECTABLE;INTRAMUSCULAR201588-001Oct 24, 2011APRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
ROPINIROLE HYDROCHLORIDE
ropinirole hydrochloride
TABLET, EXTENDED RELEASE;ORAL201047-006Jun 6, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
ROSUVASTATIN CALCIUM
rosuvastatin calcium
TABLET;ORAL079171-002Jul 19, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
KETOROLAC TROMETHAMINE
ketorolac tromethamine
INJECTABLE;INJECTION076271-002Oct 6, 2004APRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
ACETAMINOPHEN
acetaminophen
SOLUTION;IV (INFUSION)204052-001Mar 22, 2016APRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
SILODOSIN
silodosin
CAPSULE;ORAL204726-002Mar 31, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Sandoz Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,261,547 Gelling ophthalmic compositions containing xanthan gum► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sandoz Inc Drugs

Country Document Number Estimated Expiration
Australia3194799► Subscribe
Hong Kong1031335► Subscribe
TaiwanI262797► Subscribe
Spain2203103► Subscribe
Canada2322579► Subscribe
South Africa200004413► Subscribe
Japan4545927► Subscribe
World Intellectual Property Organization (WIPO)9951273► Subscribe
Canada2505836► Subscribe
China1295483► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sandoz Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0013Belgium► SubscribePRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
C/GB09/026United Kingdom► SubscribePRODUCT NAME: ESTRADIOL AND COMBINATIONS OF ESTRADIOL AND DIENOGEST, PREFERABLY ESTRADIOL VALERATE AND COMBINATIONS OF ESTRADIOL VALERATE AND DIENOGEST; REGISTERED: BE BE 327792 20081103; UK PL 00010/0576-0001 20081208
C0028France► SubscribePRODUCT NAME: EZETIMIBE; NAT. REGISTRATION NO/DATE: NL28237 20030611; FIRST REGISTRATION: DE - 54486.00.00 A 54489.00.00 20021017
545Luxembourg► SubscribePRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
/2014Austria► SubscribePRODUCT NAME: PACLITAXEL, DAS ALS ALBUMIN GEBUNDENE NANOPARTIKEL FORMUIERT IST.; REGISTRATION NO/DATE: EU/1/07/428 (MITTEILUNG) (GEAENDERT DURCH C(2013) 9835) 20131230
14/041Ireland► SubscribePRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
00099Netherlands► SubscribePRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
90007Netherlands► SubscribePRODUCT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT; REGISTRATION NO/DATE: EU/1/98/089/001-EU/1/98/089/010 19981211
90041Netherlands► SubscribePRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
2015000111Germany► SubscribePRODUCT NAME: OKULARE IRRIGATIONSLOESUNG, WELCHE PHENYLEPHRIN ODER DESSEN PHARMAZEUTISCH WIRKSAMES SALZ UND KETOROLAC ODER DESSEN PHARMAZEUTISCH WIRKSAMES SALZ UMFASST; REGISTRATION NO/DATE: EU/1/15/1018 20150728
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
McKesson
Johnson and Johnson
Federal Trade Commission
Boehringer Ingelheim
US Army
UBS
Citi
Fish and Richardson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot